Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. (RMD) is a health technology company focused on sleep, breathing, and care delivered in the home, and its news flow reflects that focus. Company announcements regularly describe how ResMed creates life-changing health technologies, combining AI-powered digital health solutions, cloud-connected devices, and intelligent software to support sleep and breathing therapy for people in more than 140 countries.
Investors following RMD news can expect updates on financial performance and capital returns, including quarterly earnings releases, dividend declarations, and details of investor webcasts. ResMed frequently issues press releases about its results of operations, margins, cash flow, and related board decisions such as quarterly cash dividends, as documented in its Form 8-K filings and Globe Newswire announcements.
ResMed’s news also highlights product and technology developments. Recent communications include FDA clearance for Smart Comfort, an AI-enabled digital medical device that recommends personalized comfort settings for CPAP therapy, and design awards for the AirTouch N30i nasal cradle mask. These stories often emphasize the use of real-world sleep data, machine learning, and human-centered design to improve comfort and adherence for people with obstructive sleep apnea.
Another recurring theme in ResMed’s news is research and clinical insights. The company has announced landmark studies in The Lancet Respiratory Medicine projecting future obstructive sleep apnea prevalence, as well as meta-analyses on CPAP therapy and mortality. It has also launched initiatives like Sleep Institute to publish evidence-based insights that inform care models and policy discussions around sleep health.
Corporate governance and investor-relations events appear frequently in RMD news as well, including participation in major healthcare conferences, updates on board composition, and details of annual meetings. For readers and investors, the RMD news page offers a centralized view of ResMed’s earnings, product clearances, research publications, and strategic initiatives related to sleep and breathing health.
ResMed (NYSE: RMD) announced its plans to release third-quarter financial results for fiscal year 2023 on April 27, after market close. The company will host a webcast at 1:30 p.m. PDT to discuss the results and share additional forward-looking information. The event demonstrates ResMed's commitment to transparency with investors and stakeholders. Following the live webcast, a replay will be available on the company’s website, providing convenient access to the information shared. ResMed, known for its innovative digital health technologies and cloud-connected medical devices, serves over 140 countries, aiming to enhance healthcare delivery for chronic conditions.
ResMed (NYSE: RMD) announced that David Pendarvis, its chief administrative officer and global general counsel, will retire on June 30, 2023, after over 20 years with the company. He will transition to a consulting role until December 31, 2023. ResMed plans to conduct an internal search for his successor, aiming for a seamless transition. Amy Wakeham, currently Vice President of Corporate Communications & Investor Relations, has been appointed as the new Chief Communications and Investor Relations Officer, effective April 1, 2023. CEO Mick Farrell praised Pendarvis for his leadership during ResMed's transformation into a $30 billion global leader in digital health.
ResMed (NYSE: RMD) announced that Rob Douglas, president and COO, will participate in a fireside chat at the 2023 KeyBanc Life Sciences & MedTech Investor Forum on March 21, 2023, at approximately 3:45 p.m. EDT. The event will be accessible via webcast. Interested parties can find more information and access the live audio-only webcast by visiting ResMed Investor Relations. A replay will be available 24 hours after the event and will remain accessible for 90 days. ResMed focuses on innovative digital health technologies and cloud-connected medical devices for chronic diseases.
ResMed (NYSE: RMD) announced that Rob Douglas, the president and COO, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at approximately 11:20 a.m. EDT. The presentation will be accessible via a webcast, and interested parties can find more information and access the live stream on ResMed's investor relations website. A replay will be available approximately 24 hours after the event and can be accessed for 90 days. ResMed specializes in innovative solutions for chronic diseases, enhancing care with digital health technologies and cloud-connected medical devices across over 140 countries.
FAQ
What is the current stock price of Resmed (RMD)?
What is the market cap of Resmed (RMD)?
